LB-1071 is under clinical development by United Laboratories International and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LB-1071’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LB-1071 is under development for the treatment of rheumatoid arthritis (RA), atopic dermatitis. It is administered through topical route and acts by targeting Janus kinase 1 (JAK1).
United Laboratories International overview
United Laboratories International (United Lab) is a pharmaceutical company that manufactures and sells pharmaceutical products. The company offers products through divisions such as preparation products, intermediate products, capsule products, raw material products, and health products. It also provides antibiotics, pharmaceutical raw materials and intermediates, material products and healthcare products. Its intermediates include amino-cephalosporanic acid, amino-penicillin acid, and octylammonium clavulanate. United Laboratories’ drug products include amoxicillin capsules, ampicillin capsules, clavulana capsules, levofloxacin hydrochlorid, and cefuroxime axetil tablets, among others. It sells its products through a network of distributors in Europe, North America, East Africa, and southeast Asia. United Lab is headquartered in Hong Kong.
For a complete picture of LB-1071’s drug-specific PTSR and LoA scores, buy the report here.